Latest Diabetic Nephropathy News
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist.
Patients with higher levels of serum fibrinogen have higher rates of progression.
Much steeper decline in adjusted mean eGFR for those with diagnosed diabetes versus those without.
New study shows metformin is not associated with an increased risk of acidosis in patients with type 2 diabetes and an eGFR of 30 to 60 mL/min/1.73 m2.
Women who had gestational diabetes more likely to show increased eGFR levels many years postpartum
Genome-wide association study identified novel signal near GABRR1, which was not seen in Asians.
Relative risk of end-stage renal disease was 0.13 in those diagnosed in 1995-2011 versus 1965-1979.
Nearly 86% of diabetic nephropathy patients from an Egyptian outpatient center had elevated iPTH levels.
2000 to 2014 saw decrease in incidence of ESRD with diabetes listed as the primary cause.
Proteinuria and renin-angiotensin-aldosterone system inhibitors are independently associated with a significant 6-fold increased odds for anemia in patients with diabetic nephropathy.
End-stage renal disease developed in similar proportions of diabetics regardless of whether they had intensive or standard glycemic control.
Biomarkers apoA4, CD5L, C1QB, and IBP3 may improve the prediction of rapid decline in renal function independently of recognized clinical risk factors in T2DM.
Liraglutide-treated patients were 22% less likely than placebo recipients to experience a composite outcome of renal events.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
Renal and Urology News Articles
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer